Business, energy, technology, markets and global industry news from Business News Today

pTau 217

PharmaDeviceNews pTau 217
Representative image: A fully automated laboratory blood-testing workflow highlights how Fujirebio’s CE-marked Lumipulse G pTau 217 Plasma assay could support scalable Alzheimer’s disease diagnostics and expand access to biomarker-based cognitive decline evaluation across Europe.
Medical Devices & Diagnostics

Why Europe’s Alzheimer’s testing pathway could shift after Fujirebio’s latest CE marking

Alzheimer’s testing needs scale, not just science. Fujirebio’s CE-marked pTau 217 assay pushes blood biomarkers closer to routine care.

Read More
Medical Devices & Diagnostics

What Spear Bio’s new pTau 217 assay reveals about where Alzheimer’s biomarker detection is heading

Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer's and Parkinson's research. Read the analysis.

Read More
Medical Devices & Diagnostics

Could Fujirebio’s pTau 217 CSF assay become a new standard in Alzheimer’s research?

Find out how Fujirebio’s new Lumipulse pTau 217 CSF assay could shape the future of Alzheimer’s biomarker research and platform-based diagnostics.

Read More